A new study from the USC Norris Comprehensive Cancer Center showed that targeting both hormone receptors and human epidermal growth factor receptor 2 in first-line treatment of metastatic breast cancer patients significantly increased overall survival times. Read more here.
Study mentioned: Tripathy D, et al. First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER. Oncologist. 2013 May 7. [Epub ahead of print] PMID: 23652380
No comments:
Post a Comment